BIA letter to the Chancellor ahead of the 2019 Spending Round
The BIA has written to the Chancellor ahead of the 2019 Spending Round to highlight how the Government should maintain a competitive life sciences environment in the UK.
Brainomix presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.
The proposals outlined in the report are a major step towards realising BIA’s long-held goal of increasing investment from UK pension funds into UK life sciences.
BIA has responded to a HMRC consultation on R&D tax relief advance clearances, supporting government's aim to reduce error and fraud, increasing certainty for R&D tax relief claimants.
WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.
Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.
